1. Macneil LT, Walhout AJ: Gene regulatory networks and the role of robustness and stochasticity in the control of gene expression. Genome Res 2011, 21(5):645-657.
2. Loscalzo J, Barabasi AL: Systems biology and the future of medicine. Wiley Interdiscip Rev Syst Biol Med 2011, 3(6):619-627.
3. Amiri-Kordestani L, Basseville A, Kurdziel K, Fojo AT, Bates SE: Targeting MDR in breast and lung cancer: discriminating its potential importance from the failure of drug resistance reversal studies. Drug Resist Updat 2012, 15(1-2):50-61.
4. Ledford H: Translational research: 4 ways to fix the clinical trial. Nature 2011, 477(7366):526-528.
5. Jacobs JJ, Snackey C, Geldof AA, Characiejus D, Van Moorselaar RJ, Den Otter W: Inefficacy of therapeutic cancer vaccines and proposed improvements. Casus of prostate cancer. Anticancer Res 2014, 34(6):2689-2700.
6. Kohler S: Precision medicine –moving away from one-size-fits-all. Academy of Science for South Africa (ASSAf) 2018, 14(3):12-15.
7. Tiriveedhi V: Impact of Precision Medicine on Drug Repositioning and Pricing: A Too Small to Thrive Crisis. J Pers Med 2018, 8(4).
8. Gjuvsland AB, Vik JO, Beard DA, Hunter PJ, Omholt SW: Bridging the genotype- phenotype gap: what does it take? J Physiol 2013, 591(8):2055-2066.
9. Ritchie MD, Holzinger ER, Li R, Pendergrass SA, Kim D: Methods of integrating data to uncover genotype-phenotype interactions. Nat Rev Genet 2015, 16(2):85-97.
10. Gallo Cantafio ME, Grillone K, Caracciolo D, Scionti F, Arbitrio M, Barbieri V, Pensabene L, Guzzi PH, Di Martino MT: From Single Level Analysis to Multi-Omics Integrative Approaches: A Powerful Strategy towards the Precision Oncology. High Throughput 2018, 7(4).
11. Dudley JT, Schadt E, Sirota M, Butte AJ, Ashley E: Drug discovery in a multidimensional world: systems, patterns, and networks. J Cardiovasc Transl Res 2010, 3(5):438-447.
12. Rattray NJW, Deziel NC, Wallach JD, Khan SA, Vasiliou V, Ioannidis JPA, Johnson CH: Beyond genomics: understanding exposotypes through metabolomics. Hum Genomics 2018, 12(1):4.
13. Elad Noor SC, UweSauer: Biological insights through omics data integration. Current Opinion in Systems Biology 2019, 15:39-47.
14. van Dam S, Vosa U, van der Graaf A, Franke L, de Magalhaes JP: Gene co-expression analysis for functional classification and gene-disease predictions. Brief Bioinform 2018, 19(4):575-592.
15. Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos BH, Lindborg SR, Schacht AL: How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat Rev Drug Discov 2010, 9(3):203-214.
16. Li YY, Jones SJ: Drug repositioning for personalized medicine. Genome Med 2012, 4(3):27.
17. Younesi E, Hofmann-Apitius M: From integrative disease modeling to predictive, preventive, personalized and participatory (P4) medicine. EPMA J 2013, 4(1):23.
18. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and- statistics/annual-cancer-facts-and-figures/2017/cancer-facts-and-figures-2017.pdf. Cancer Facts Figures 2017.
19. Institute NC Surveillance, Epidemiology, and End Results (SEER) Program 2007- 2013.
20. Sandborn WJ: The Present and Future of Inflammatory Bowel Disease Treatment. Gastroenterol Hepatol (N Y) 2016, 12(7):438-441.
21. Huang CT, Hsieh CH, Oyang YJ, Huang HC, Juan HF: A Large-Scale Gene Expression Intensity-Based Similarity Metric for Drug Repositioning. iScience 2018, 7:40-52.
22. Kondo M, Wagers AJ, Manz MG, Prohaska SS, Scherer DC, Beilhack GF, Shizuru JA, Weissman IL: Biology of hematopoietic stem cells and progenitors: implications for clinical application. Annu Rev Immunol 2003, 21:759-806.
23. Warner JK, Wang JC, Hope KJ, Jin L, Dick JE: Concepts of human leukemic development. Oncogene 2004, 23(43):7164-7177.
24. Tenen DG: Disruption of differentiation in human cancer: AML shows the way. Nat Rev Cancer 2003, 3(2):89-101.
25. Shi Y, Lan F, Matson C, Mulligan P, Whetstine JR, Cole PA, Casero RA: Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell 2004, 119(7):941-953.
26. Shi YJ, Matson C, Lan F, Iwase S, Baba T, Shi Y: Regulation of LSD1 histone demethylase activity by its associated factors. Mol Cell 2005, 19(6):857-864.
27. van der Meer LT, Jansen JH, van der Reijden BA: Gfi1 and Gfi1b: key regulators of hematopoiesis. Leukemia 2010, 24(11):1834-1843.
28. Saleque S, Kim J, Rooke HM, Orkin SH: Epigenetic regulation of hematopoietic differentiation by Gfi-1 and Gfi-1b is mediated by the cofactors CoREST and LSD1. Mol Cell 2007, 27(4):562-572.
29. Kerenyi MA, Shao Z, Hsu YJ, Guo G, Luc S, O'Brien K, Fujiwara Y, Peng C, Nguyen M, Orkin SH: Histone demethylase Lsd1 represses hematopoietic stem and progenitor cell signatures during blood cell maturation. Elife 2013, 2:e00633.
30. Sprussel A, Schulte JH, Weber S, Necke M, Handschke K, Thor T, Pajtler KW, Schramm A, Konig K, Diehl L et al: Lysine-specific demethylase 1 restricts hematopoietic progenitor proliferation and is essential for terminal differentiation. Leukemia 2012, 26(9):2039-2051.
31. Harris WJ, Huang X, Lynch JT, Spencer GJ, Hitchin JR, Li Y, Ciceri F, Blaser JG, Greystoke BF, Jordan AM et al: The histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cells. Cancer Cell 2012, 21(4):473- 487.
32. Lynch JT, Harris WJ, Somervaille TC: LSD1 inhibition: a therapeutic strategy in cancer? Expert Opin Ther Targets 2012, 16(12):1239-1249.
33. Schenk T, Chen WC, Gollner S, Howell L, Jin L, Hebestreit K, Klein HU, Popescu AC, Burnett A, Mills K et al: Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia. Nat Med 2012, 18(4):605-611.
34. Fiskus W, Sharma S, Shah B, Portier BP, Devaraj SG, Liu K, Iyer SP, Bearss D, Bhalla KN: Highly effective combination of LSD1 (KDM1A) antagonist and pan- histone deacetylase inhibitor against human AML cells. Leukemia 2014, 28(11):2155- 2164.
35. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES et al: Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 2005, 102(43):15545-15550.
36. Dougherty JD, Schmidt EF, Nakajima M, Heintz N: Analytical approaches to RNA profiling data for the identification of genes enriched in specific cells. Nucleic Acids Res 2010, 38(13):4218-4230.
37. Ueda R, Suzuki T, Mino K, Tsumoto H, Nakagawa H, Hasegawa M, Sasaki R, Mizukami T, Miyata N: Identification of cell-active lysine specific demethylase 1- selective inhibitors. J Am Chem Soc 2009, 131(48):17536-17537.
38. Nerlov C, Graf T: PU.1 induces myeloid lineage commitment in multipotent hematopoietic progenitors. Genes Dev 1998, 12(15):2403-2412.
39. van Bergen M, van der Reijden BA: Targeting the GFI1/1B-CoREST Complex in Acute Myeloid Leukemia. Front Oncol 2019, 9:1027.
40. Huang DY, Kuo YY, Chang ZF: GATA-1 mediates auto-regulation of Gfi-1B transcription in K562 cells. Nucleic Acids Res 2005, 33(16):5331-5342.
41. McGrath JP, Williamson KE, Balasubramanian S, Odate S, Arora S, Hatton C, Edwards TM, O'Brian T, Magnuson S, Stokoe D et al: Pharmacological inhibition of the histone lysine demethylase KDM1A suppresses the growth of multiple acute myeloid leukemia subtypes. Cancer Res 2016.
42. Foudi A, Kramer DJ, Qin J, Ye D, Behlich AS, Mordecai S, Preffer FI, Amzallag A, Ramaswamy S, Hochedlinger K et al: Distinct, strict requirements for Gfi-1b in adult bone marrow red cell and platelet generation. J Exp Med 2014, 211(5):909-927.
43. Castoldi GL, Liso V, Fenu S, Vegna ML, Mandelli F: Reproducibility of the morphological diagnostic criteria for acute myeloid leukemia: the GIMEMA group experience. Ann Hematol 1993, 66(4):171-174.
44. Pagano L, Pulsoni A, Vignetti M, Mele L, Fianchi L, Petti MC, Mirto S, Falcucci P, Fazi P, Broccia G et al: Acute megakaryoblastic leukemia: experience of GIMEMA trials. Leukemia 2002, 16(9):1622-1626.
45. Santos FP, Faderl S, Garcia-Manero G, Koller C, Beran M, O'Brien S, Pierce S, Freireich EJ, Huang X, Borthakur G et al: Adult acute erythroleukemia: an analysis of 91 patients treated at a single institution. Leukemia 2009, 23(12):2275-2280.
46. Oki Y, Kantarjian HM, Zhou X, Cortes J, Faderl S, Verstovsek S, O'Brien S, Koller C, Beran M, Bekele BN et al: Adult acute megakaryocytic leukemia: an analysis of 37 patients treated at M.D. Anderson Cancer Center. Blood 2006, 107(3):880-884.
47. Cervera N, Carbuccia N, Garnier S, Guille A, Adelaide J, Murati A, Vey N, Mozziconacci MJ, Chaffanet M, Birnbaum D et al: Molecular characterization of acute erythroid leukemia (M6-AML) using targeted next-generation sequencing. Leukemia 2015.
48. Wang ZY, Chen Z: Acute promyelocytic leukemia: from highly fatal to highly curable. Blood 2008, 111(5):2505-2515.
49. Saleque S, Cameron S, Orkin SH: The zinc-finger proto-oncogene Gfi-1b is essential for development of the erythroid and megakaryocytic lineages. Genes Dev 2002, 16(3):301-306.
50. Elmaagacli AH, Koldehoff M, Zakrzewski JL, Steckel NK, Ottinger H, Beelen DW: Growth factor-independent 1B gene (GFI1B) is overexpressed in erythropoietic and megakaryocytic malignancies and increases their proliferation rate. Br J Haematol 2007, 136(2):212-219.
51. Anguita E, Gupta R, Olariu V, Valk PJ, Peterson C, Delwel R, Enver T: A somatic mutation of GFI1B identified in leukemia alters cell fate via a SPI1 (PU.1) centered genetic regulatory network. Dev Biol 2016, 411(2):277-286.
52. Vianello P, Botrugno OA, Cappa A, Ciossani G, Dessanti P, Mai A, Mattevi A, Meroni G, Minucci S, Thaler F et al: Synthesis, biological activity and mechanistic insights of 1-substituted cyclopropylamine derivatives: a novel class of irreversible inhibitors of histone demethylase KDM1A. Eur J Med Chem 2014, 86:352-363.
53. Maes T, Mascaro C, Ortega A, Lunardi S, Ciceri F, Somervaille TC, Buesa C: KDM1 histone lysine demethylases as targets for treatments of oncological and neurodegenerative disease. Epigenomics 2015, 7(4):609-626.
54. Zheng YC, Ma J, Wang Z, Li J, Jiang B, Zhou W, Shi X, Wang X, Zhao W, Liu HM: A Systematic Review of Histone Lysine-Specific Demethylase 1 and Its Inhibitors. Med Res Rev 2015, 35(5):1032-1071.
55. Mohammad HP, Smitheman KN, Kamat CD, Soong D, Federowicz KE, Van Aller GS, Schneck JL, Carson JD, Liu Y, Butticello M et al: A DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 Inhibitors in SCLC. Cancer Cell 2015, 28(1):57- 69.
56. Randrianarison-Huetz V, Laurent B, Bardet V, Blobe GC, Huetz F, Dumenil D: Gfi- 1B controls human erythroid and megakaryocytic differentiation by regulating TGF- beta signaling at the bipotent erythro-megakaryocytic progenitor stage. Blood 2010, 115(14):2784-2795.
57. Lichtenstein GR, Abreu MT, Cohen R, Tremaine W: American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 2006, 130(3):935-939.
58. Rutgeerts P, D'Haens G, Targan S, Vasiliauskas E, Hanauer SB, Present DH, Mayer L, Van Hogezand RA, Braakman T, DeWoody KL et al: Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 1999, 117(4):761-769.
59. Lakatos PL, Golovics PA, David G, Pandur T, Erdelyi Z, Horvath A, Mester G, Balogh M, Szipocs I, Molnar C et al: Has there been a change in the natural history of Crohn's disease? Surgical rates and medical management in a population-based inception cohort from Western Hungary between 1977-2009. Am J Gastroenterol 2012, 107(4):579-588.
60. Lazarev M, Ullman T, Schraut WH, Kip KE, Saul M, Regueiro M: Small bowel resection rates in Crohn's disease and the indication for surgery over time: experience from a large tertiary care center. Inflamm Bowel Dis 2010, 16(5):830-835.
61. Peyrin-Biroulet L, Loftus EV, Jr., Colombel JF, Sandborn WJ: The natural history of adult Crohn's disease in population-based cohorts. Am J Gastroenterol 2010, 105(2):289-297.
62. Gisbert JP, Marin AC, Chaparro M: The Risk of Relapse after Anti-TNF Discontinuation in Inflammatory Bowel Disease: Systematic Review and Meta- Analysis. Am J Gastroenterol 2016, 111(5):632-647.
63. Boyapati R, Satsangi J, Ho GT: Pathogenesis of Crohn's disease. F1000Prime Rep 2015, 7:44.
64. Talley NJ, Abreu MT, Achkar JP, Bernstein CN, Dubinsky MC, Hanauer SB, Kane SV, Sandborn WJ, Ullman TA, Moayyedi P: An evidence-based systematic review on medical therapies for inflammatory bowel disease. Am J Gastroenterol 2011, 106 Suppl 1:S2-25; quiz S26.
65. Zallot C, Peyrin-Biroulet L: Deep remission in inflammatory bowel disease: looking beyond symptoms. Curr Gastroenterol Rep 2013, 15(3):315.
66. Kiesslich R, Duckworth CA, Moussata D, Gloeckner A, Lim LG, Goetz M, Pritchard DM, Galle PR, Neurath MF, Watson AJ: Local barrier dysfunction identified by confocal laser endomicroscopy predicts relapse in inflammatory bowel disease. Gut 2012, 61(8):1146-1153.
67. D'Haens G, Van Deventer S, Van Hogezand R, Chalmers D, Kothe C, Baert F, Braakman T, Schaible T, Geboes K, Rutgeerts P: Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial. Gastroenterology 1999, 116(5):1029-1034.
68. Bai JP, Alekseyenko AV, Statnikov A, Wang IM, Wong PH: Strategic applications of gene expression: from drug discovery/development to bedside. Aaps J 2013, 15(2):427- 437.
69. Chen B, Butte AJ: Leveraging big data to transform target selection and drug discovery. Clin Pharmacol Ther 2016, 99(3):285-297.
70. Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ, Lerner J, Brunet JP, Subramanian A, Ross KN et al: The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 2006, 313(5795):1929-1935.
71. Cheng J, Yang L, Kumar V, Agarwal P: Systematic evaluation of connectivity map for disease indications. Genome Med 2014, 6(12):540.
72. Arijs I, De Hertogh G, Lemaire K, Quintens R, Van Lommel L, Van Steen K, Leemans P, Cleynen I, Van Assche G, Vermeire S et al: Mucosal gene expression of antimicrobial peptides in inflammatory bowel disease before and after first infliximab treatment. PLoS One 2009, 4(11):e7984.
73. D'Haens GR, Geboes K, Peeters M, Baert F, Penninckx F, Rutgeerts P: Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology 1998, 114(2):262-267.
74. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, Travers S, Rachmilewitz D, Hanauer SB, Lichtenstein GR et al: Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005, 353(23):2462-2476.
75. Geboes K, Riddell R, Ost A, Jensfelt B, Persson T, Lofberg R: A reproducible grading scale for histological assessment of inflammation in ulcerative colitis. Gut 2000, 47(3):404-409.
76. Jung P, Sato T, Merlos-Suarez A, Barriga FM, Iglesias M, Rossell D, Auer H, Gallardo M, Blasco MA, Sancho E et al: Isolation and in vitro expansion of human colonic stem cells. Nat Med 2011, 17(10):1225-1227.
77. Merlos-Suarez A, Barriga FM, Jung P, Iglesias M, Cespedes MV, Rossell D, Sevillano M, Hernando-Momblona X, da Silva-Diz V, Munoz P et al: The intestinal stem cell signature identifies colorectal cancer stem cells and predicts disease relapse. Cell Stem Cell 2011, 8(5):511-524.
78. Adams ME, Wallace MB, Kanouni T, Scorah N, O'Connell SM, Miyake H, Shi L, Halkowycz P, Zhang L, Dong Q: Design and synthesis of orally available MEK inhibitors with potent in vivo antitumor efficacy. Bioorg Med Chem Lett 2012, 22(7):2411-2414.
79. Alhnan MA, Basit AW: Engineering polymer blend microparticles: an investigation into the influence of polymer blend distribution and interaction. Eur J Pharm Sci 2011, 42(1-2):30-36.
80. Kendall RA, Alhnan MA, Nilkumhang S, Murdan S, Basit AW: Fabrication and in vivo evaluation of highly pH-responsive acrylic microparticles for targeted gastrointestinal delivery. Eur J Pharm Sci 2009, 37(3-4):284-290.
81. Mele M, Ferreira PG, Reverter F, DeLuca DS, Monlong J, Sammeth M, Young TR, Goldmann JM, Pervouchine DD, Sullivan TJ et al: Human genomics. The human transcriptome across tissues and individuals. Science 2015, 348(6235):660-665.
82. Dudley JT, Sirota M, Shenoy M, Pai RK, Roedder S, Chiang AP, Morgan AA, Sarwal MM, Pasricha PJ, Butte AJ: Computational repositioning of the anticonvulsant topiramate for inflammatory bowel disease. Sci Transl Med 2011, 3(96):96ra76.
83. Dry JR, Pavey S, Pratilas CA, Harbron C, Runswick S, Hodgson D, Chresta C, McCormack R, Byrne N, Cockerill M et al: Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244). Cancer Res 2010, 70(6):2264-2273.
84. Saaf AM, Halbleib JM, Chen X, Yuen ST, Leung SY, Nelson WJ, Brown PO: Parallels between global transcriptional programs of polarizing Caco-2 intestinal epithelial cells in vitro and gene expression programs in normal colon and colon cancer. Mol Biol Cell 2007, 18(11):4245-4260.
85. Bregenholt S, Reimann J, Claesson MH: Proliferation and apoptosis of lamina propria CD4+ T cells from scid mice with inflammatory bowel disease. Eur J Immunol 1998, 28(11):3655-3663.
86. Zhao Y, Adjei AA: The clinical development of MEK inhibitors. Nat Rev Clin Oncol 2014, 11(7):385-400.
87. Hua S, Marks E, Schneider JJ, Keely S: Advances in oral nano-delivery systems for colon targeted drug delivery in inflammatory bowel disease: selective targeting to diseased versus healthy tissue. Nanomedicine 2015, 11(5):1117-1132.
88. Lapidus A, Bernell O, Hellers G, Lofberg R: Clinical course of colorectal Crohn's disease: a 35-year follow-up study of 507 patients. Gastroenterology 1998, 114(6):1151-1160.
89. Chauvin A, Le Thuaut A, Belhassan M, Le Baleur Y, Mesli F, Bastuji-Garin S, Delchier JC, Amiot A: Infliximab as a bridge to remission maintained by antimetabolite therapy in Crohn's disease: A retrospective study. Dig Liver Dis 2014, 46(8):695-700.
90. Coskun M: Intestinal epithelium in inflammatory bowel disease. Front Med (Lausanne) 2014, 1:24.
91. Peterson LW, Artis D: Intestinal epithelial cells: regulators of barrier function and immune homeostasis. Nat Rev Immunol 2014, 14(3):141-153.
92. Pastorelli L, De Salvo C, Mercado JR, Vecchi M, Pizarro TT: Central role of the gut epithelial barrier in the pathogenesis of chronic intestinal inflammation: lessons learned from animal models and human genetics. Front Immunol 2013, 4:280.
93. Koch S, Nusrat A: The life and death of epithelia during inflammation: lessons learned from the gut. Annu Rev Pathol 2012, 7:35-60.
94. D'Inca R, Di Leo V, Corrao G, Martines D, D'Odorico A, Mestriner C, Venturi C, Longo G, Sturniolo GC: Intestinal permeability test as a predictor of clinical course in Crohn's disease. Am J Gastroenterol 1999, 94(10):2956-2960.
95. Arnott ID, Kingstone K, Ghosh S: Abnormal intestinal permeability predicts relapse in inactive Crohn disease. Scand J Gastroenterol 2000, 35(11):1163-1169.
96. Vereecke L, Beyaert R, van Loo G: Enterocyte death and intestinal barrier maintenance in homeostasis and disease. Trends Mol Med 2011, 17(10):584-593.
97. Suarez-Farinas M, Fuentes-Duculan J, Lowes MA, Krueger JG: Resolved psoriasis lesions retain expression of a subset of disease-related genes. J Invest Dermatol 2011, 131(2):391-400.
98. Planell N, Lozano JJ, Mora-Buch R, Masamunt MC, Jimeno M, Ordas I, Esteller M, Ricart E, Pique JM, Panes J et al: Transcriptional analysis of the intestinal mucosa of patients with ulcerative colitis in remission reveals lasting epithelial cell alterations. Gut 2013, 62(7):967-976.
99. Zeissig S, Bergann T, Fromm A, Bojarski C, Heller F, Guenther U, Zeitz M, Fromm M, Schulzke JD: Altered ENaC expression leads to impaired sodium absorption in the noninflamed intestine in Crohn's disease. Gastroenterology 2008, 134(5):1436- 1447.
100. Herr R, Kohler M, Andrlova H, Weinberg F, Moller Y, Halbach S, Lutz L, Mastroianni J, Klose M, Bittermann N et al: B-Raf inhibitors induce epithelial differentiation in BRAF-mutant colorectal cancer cells. Cancer Res 2015, 75(1):216-229.
101. Lemieux E, Boucher MJ, Mongrain S, Boudreau F, Asselin C, Rivard N: Constitutive activation of the MEK/ERK pathway inhibits intestinal epithelial cell differentiation. Am J Physiol Gastrointest Liver Physiol 2011, 301(4):G719-730.
102. Coskun M: The role of CDX2 in inflammatory bowel disease. Dan Med J 2014, 61(3):B4820.
103. Gao N, White P, Kaestner KH: Establishment of intestinal identity and epithelial- mesenchymal signaling by Cdx2. Dev Cell 2009, 16(4):588-599.
104. Dedhia PH, Bertaux-Skeirik N, Zavros Y, Spence JR: Organoid Models of Human Gastrointestinal Development and Disease. Gastroenterology 2016, 150(5):1098-1112.
105. Liu F, Huang J, Ning B, Liu Z, Chen S, Zhao W: Drug Discovery via Human-Derived Stem Cell Organoids. Front Pharmacol 2016, 7:334.
106. Du SL, Yuan X, Zhan S, Tang LJ, Tong CY: Trametinib, a novel MEK kinase inhibitor, suppresses lipopolysaccharide-induced tumor necrosis factor (TNF)-alpha production and endotoxin shock. Biochem Biophys Res Commun 2015, 458(3):667-673.
107. Sirota M, Dudley JT, Kim J, Chiang AP, Morgan AA, Sweet-Cordero A, Sage J, Butte AJ: Discovery and preclinical validation of drug indications using compendia of public gene expression data. Sci Transl Med 2011, 3(96):96ra77.
108. Jahchan NS, Dudley JT, Mazur PK, Flores N, Yang D, Palmerton A, Zmoos AF, Vaka D, Tran KQ, Zhou M et al: A drug repositioning approach identifies tricyclic antidepressants as inhibitors of small cell lung cancer and other neuroendocrine tumors. Cancer Discov 2013, 3(12):1364-1377.
109. Zerbini LF, Bhasin MK, de Vasconcellos JF, Paccez JD, Gu X, Kung AL, Libermann TA: Computational repositioning and preclinical validation of pentamidine for renal cell cancer. Mol Cancer Ther 2014, 13(7):1929-1941.
110. Claerhout S, Lim JY, Choi W, Park YY, Kim K, Kim SB, Lee JS, Mills GB, Cho JY: Gene expression signature analysis identifies vorinostat as a candidate therapy for gastric cancer. PLoS One 2011, 6(9):e24662.
111. Hirose M, Okaniwa M, Hayashi Y, Takagi T: Preparation of heterocyclic compounds as Raf inhibitors for treatment of cancer. Patent WO2009028629 A1 March 5, 2009.
112. Ishikawa T, Banno H, Kawakita Y, Ohashi T, Kurasawa O: Preparation of fused heterocyclic compounds as tyrosine kinase inhibitors. Patent WO2008072634 A1 June 19, 2008.
113. Kawakita Y, Miwa K, Seto M, Banno H, Ohta Y, Tamura T, Yusa T, Miki H, Kamiguchi H, Ikeda Y et al: Design and synthesis of pyrrolo[3,2-d]pyrimidine HER2/EGFR dual inhibitors: improvement of the physicochemical and pharmacokinetic profiles for potent in vivo anti-tumor efficacy. Bioorg Med Chem 2012, 20(20):6171-6180.
114. Hirose M, Okaniwa M, Miyazaki T, Imada T, Ohashi T, Tanaka Y, Arita T, Yabuki M, Kawamoto T, Tsutsumi S et al: Design and synthesis of novel DFG-out RAF/vascular endothelial growth factor receptor 2 (VEGFR2) inhibitors: 3. Evaluation of 5-amino- linked thiazolo[5,4-d]pyrimidine and thiazolo[5,4-b]pyridine derivatives. Bioorg Med Chem 2012, 20(18):5600-5615.
115. Barrett SD, Bridges AJ, Dudley DT, Saltiel AR, Fergus JH, Flamme CM, Delaney AM, Kaufman M, LePage S, Leopold WR et al: The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901. Bioorg Med Chem Lett 2008, 18(24):6501- 6504.
116. Mini E, Nobili S, Caciagli B, Landini I, Mazzei T: Cellular pharmacology of gemcitabine. Ann Oncol 2006, 17 Suppl 5:v7-12.
117. Dong Q, Feher V, Kaldor SW, Tomita N: MEK1/2 inhibitors, methods for their synthesis, and their use in disease treatment. Patent US20080125437 A1 May 29, 2008.
118. Ishikawa T, Seto M, Banno H, Kawakita Y, Oorui M, Taniguchi T, Ohta Y, Tamura T, Nakayama A, Miki H et al: Design and synthesis of novel human epidermal growth factor receptor 2 (HER2)/epidermal growth factor receptor (EGFR) dual inhibitors bearing a pyrrolo[3,2-d]pyrimidine scaffold. J Med Chem 2011, 54(23):8030-8050.
119. Dong Q, Dougan DR, Gong X, Halkowycz P, Jin B, Kanouni T, O'Connell SM, Scorah N, Shi L, Wallace MB et al: Discovery of TAK-733, a potent and selective MEK allosteric site inhibitor for the treatment of cancer. Bioorg Med Chem Lett 2011, 21(5):1315-1319.
120. Schellhammer PF: An evaluation of bicalutamide in the treatment of prostate cancer. Expert Opin Pharmacother 2002, 3(9):1313-1328.
121. Davidson EH: Emerging properties of animal gene regulatory networks. Nature 2010, 468(7326):911-920.
122. Ptasinska A, Assi SA, Martinez-Soria N, Imperato MR, Piper J, Cauchy P, Pickin A, James SR, Hoogenkamp M, Williamson D et al: Identification of a dynamic core transcriptional network in t(8;21) AML that regulates differentiation block and self- renewal. Cell Rep 2014, 8(6):1974-1988.
123. Saeed S, Logie C, Francoijs KJ, Frige G, Romanenghi M, Nielsen FG, Raats L, Shahhoseini M, Huynen M, Altucci L et al: Chromatin accessibility, p300, and histone acetylation define PML-RARalpha and AML1-ETO binding sites in acute myeloid leukemia. Blood 2012, 120(15):3058-3068.
124. Schwieger M, Schuler A, Forster M, Engelmann A, Arnold MA, Delwel R, Valk PJ, Lohler J, Slany RK, Olson EN et al: Homing and invasiveness of MLL/ENL leukemic cells is regulated by MEF2C. Blood 2009, 114(12):2476-2488.
125. Chong CR, Sullivan DJ, Jr.: New uses for old drugs. Nature 2007, 448(7154):645-646.
126. Ashburn TT, Thor KB: Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov 2004, 3(8):673-683.
127. Saiyed MM, Ong PS, Chew L: Off-label drug use in oncology: a systematic review of literature. J Clin Pharm Ther 2017, 42(3):251-258.
128. Ching KA, Wang K, Kan Z, Fernandez J, Zhong W, Kostrowicki J, Xie T, Zhu Z, Martini JF, Koehler M et al: Cell Index Database (CELLX): a web tool for cancer precision medicine. Pac Symp Biocomput 2015:10-19.
129. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, Wilson CJ, Lehar J, Kryukov GV, Sonkin D et al: The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012, 483(7391):603-607.
130. Clarke R, Ressom HW, Wang A, Xuan J, Liu MC, Gehan EA, Wang Y: The properties of high-dimensional data spaces: implications for exploring gene and protein expression data. Nat Rev Cancer 2008, 8(1):37-49.
131. Keenan AB, Jenkins SL, Jagodnik KM, Koplev S, He E, Torre D, Wang Z, Dohlman AB, Silverstein MC, Lachmann A et al: The Library of Integrated Network-Based Cellular Signatures NIH Program: System-Level Cataloging of Human Cells Response to Perturbations. Cell Syst 2018, 6(1):13-24.
132. Subramanian A, Narayan R, Corsello SM, Peck DD, Natoli TE, Lu X, Gould J, Davis JF, Tubelli AA, Asiedu JK et al: A Next Generation Connectivity Map: L1000 Platform and the First 1,000,000 Profiles. Cell 2017, 171(6):1437-1452 e1417.
133. Magliulo D, Bernardi R, Messina S: Lysine-Specific Demethylase 1A as a Promising Target in Acute Myeloid Leukemia. Front Oncol 2018, 8:255.
論文の公開元へ
